^
Association details:
Biomarker:IRF8 overexpression + ER negative
Cancer:Breast Cancer
Regimen:FAC (5-fluorouracil + cyclophosphamide + doxorubicin hydrochloride)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.

Published date:
03/25/2021
Excerpt:
In contrast, in ER-negative BC (TNBC or HER2+), high expression levels of IRF8 was significantly associated with complete pathological response in patients treated with FAC (p = 0.0003) or trastuzumab (p = 0.027) but not CMF (p = 0.746) (Fig. 4).
DOI:
10.1186/s13058-021-01418-7